Access to Medicine

Colombian Submission to the WHO IGWG negotiation favors drug company positions on IP

Posted on by Judit Rius

By resolution WHA 59.24, the WHO’s Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) has the goal of producing a Global Strategy and Plan of Action that will implement the CIPIH report recommendations and “secure an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries, proposing cle Continue Reading →

Thailand’s Compulsory Licensing Controversy

Posted on by James Love

Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel).  The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US… Continue Reading →

Notes from March 16th 2007 U.S. Capitol Briefing on Thailand’s Compulsory Licenses

Posted on by KEI Staff

On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading →

European Commission Response to CPTech Letter Regarding EU Opt-out of WTO Compulsory Licensing Mechanism

Posted on by KEI Staff

Original page: http://www.cptech.org/ip/wto/p6/eu12052005.pdf Letter from CPTech referenced available here: https://www.keionline.org/32641 MARKOS KYPRIANOU                                            PETER MANDELSON Member of the European Commission … Continue Reading →